-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 10, the official website of NMPA revealed that Zai Lab's new class 1 drug ZL-2401 (Omadacycline tosylate) has entered the "under review" stage and is expected to be approved in the near future
From: NMPA official website
Omacycline tosylate is a systemic antibacterial drug used for acute bacterial skin and skin structure infections
Omadacycline is a new type of broad-spectrum tetracycline derivative, aminomethylcycline, which has two dosage forms: oral and intravenous (IV), and is administered once a day
The drug was developed by Paratek Pharmaceuticals.
According to the Insight database, the ZL-2401 project was first approved for clinical use in July 2018, started clinical trials in December of the same year, and declared for listing in February 2020.
Omadacycline project time axis (Insight)
From the Insight database (http://db.
In March 2020, Hisun issued an announcement announcing that Sun Company Huizheng (Shanghai) Pharmaceutical Technology Co.
According to the announcement, as part of the consideration that Zai Lab granted Huizheng rights under the agreement, Huizheng paid a non-deductible advance payment of RMB 230 million to Zai Lab
